Medicare negotiations underway to lower prices for next batch of drugs

Medicare negotiations for a second batch of 15 drugs, including Novo Nordisk's Ozempic and Amgen's Otezla, are underway with opening price offers exchanged, potentially leading to price cuts effective January 2027; this follows the initial round of negotiations from the Inflation Reduction Act, which resulted in price reductions ranging from 38% to 79% for the first 10 drugs, though the future of the program remains uncertain given potential challenges from a future Trump administration despite current progress.

Analysis

Medicare drug price negotiations for a second batch of 15 drugs are actively underway, with pharmaceutical companies Novo Nordisk (NVO) and Amgen (AMGN) confirming receipt of opening price offers from the U.S. government. This round includes high-profile drugs such as Novo Nordisk's Ozempic and Amgen's Otezla. The negotiations, which could extend through October with final prices announced by November 30, aim to implement lower prices effective January 2027. This follows the first round of negotiations under the Inflation Reduction Act, which resulted in price reductions ranging from 38% for Imbruvica to 79% for Januvia, with those prices set to take effect in January 2026, establishing a significant precedent. While these negotiations were initiated during the Biden administration, the article indicates they are proceeding under the Trump administration, which has reportedly allowed the process to continue, exemplified by the Centers for Medicare and Medicaid Services issuing draft guidance for a third round. However, this continuation faces potential headwinds, as conservative platforms like Project 2025, echoed by President Trump, advocate for the repeal of Medicare drug price negotiation authority. The per-ticker sentiment for both NVO and AMGN is notably negative (-0.6), reflecting market apprehension about the potential impact of these price reductions on company revenues.

Key Decisions for Investors

• Investors holding Novo Nordisk and Amgen should closely monitor the negotiation outcomes, as material price cuts on key drugs like Ozempic and Otezla, anticipated by November 30, could significantly impact future Medicare-derived revenues and profitability.
• The continuation of these drug price negotiations signals persistent pricing pressure across the pharmaceutical sector; portfolio managers should assess exposure to companies with significant revenue from drugs potentially eligible for future negotiation rounds.
• Given the political crosscurrents, including calls for repeal from influential conservative groups despite the current administration's apparent continuation of the program, investors must factor in the heightened regulatory and political uncertainty surrounding the long-term viability of Medicare drug price negotiations when evaluating pharmaceutical investments.